Oncotarget

In The News



Artificial intelligence and blockchain companies partner to advance healthcare research


2017-08-15
Artificial intelligence and blockchain companies partner to advance healthcare research The Bitfury Group and Insilico Medicine partner to develop AI healthcare Blockchain solutions InSilico Medicine, Inc.

IMAGE: Insilico Medicine, Inc., and the Bitfury Group collaborate to develop AI healthcare Blockchain solutions. view more Credit: Insilico Medicine, Inc.

Tuesday, 15th of August, 2017, Baltimore, MD - Insilico Medicine, Inc, a Baltimore-based next-generation artificial intelligence... continue reading >>



Biogerontology Research Foundation salutes staff on multi-year drug development agreement


2017-08-14
Biogerontology Research Foundation salutes staff on multi-year drug development agreement Biogerontology Research Foundation

IMAGE: This is the Juvenescence AI Logo. view more Credit: Juvenescence AI

Tuesday, Aug. 14th, 2017, London, UK: Biogerontology Research Foundation (BGRF) Chief Science Officer Alex Zhavoronkov and BGRF Trustee Jim Mellon announce a multi-year drug development agreement, whereby Juvenescence Limited (led by Jim Mellon) will utilize leads generated by Insilico Medicine... continue reading >>



Life Extension Daily News


2017-08-11

partnered with the Baltimore -based company, Insilico Medicine, specializing in AI to find molecules that can be developed into drugs to cure and prevent these diseases. The objective of this collaboration is to increase health span for everyone on the planet. "Many of the diseases of aging are associated with the failure of the DNA repair mechanisms. The aging processes accelerate as the DNA repair mechanisms lose function. The collaboration with Insilico Medicine will allow us to find the... continue reading >>



Exploiting Cancer's Achilles Heel to Improve Treatment Options


2017-08-04
Scientists have developed a new strategy to target cancerous cells, while leaving normal cells alone.

Although cancer treatments can be effective, they are a double-edged sword because they attack all cells in the body, both cancerous and healthy.

In a study published in Oncotarget , investigators developed and conducted a novel synthetic lethality screen to identify molecules that target genetically modified yeast with a loss of the tumor suppressor protein NF1 .

The investigators could... continue reading >>



Biohaven Pharmaceutical : First molecules discovered by next-generation artificial intelligence to be developed into drugs | 4-Traders


2017-08-03
By a News Reporter-Staff News Editor at Biotech Week -- Thursday, , Baltimore, Md. , Insilico Medicine ("Insilico"), a Baltimore -based leader in artificial intelligence ("AI") for drug discovery and biomarker development, is pleased to announce a multi-year drug development agreement with the biotechnology company Juvenescence AI Limited ("Juvenescence AI"). Juvenescence AI will develop the first compounds generated by Insilico's deep-learned drug discovery engines, which train over... continue reading >>


Artificial intelligence for human age-reversal


2017-08-03
Artificial intelligence for human age-reversal Center for Healthy Aging at the University of Copenhagen has announced a research collaboration with a company specializing in artificial intelligence (AI) to develop solutions for preventing early aging. The aim of this partnership is to develop medicines to prevent and cure a broad range of diseases associated with aging such as Alzheimer's, Parkinson's and cardiovascular diseases. Alzheimer's, Parkinson's and cardiovascular diseases are... continue reading >>


Biohaven Pharmaceutical : Juvenescence AI to develop first compounds generated by Insilico`s deep-learned drug discovery engines | 4-Traders


2017-07-29
Insilico Medicine, a Baltimore -based leader in artificial intelligence ("AI") for drug discovery and biomarker development, is pleased to announce a multi-year drug development agreement with the biotechnology company Juvenescence AI Limited ("Juvenescence AI"). Juvenescence AI will develop the first compounds generated by Insilico`s deep-learned drug discovery engines, which train over structural, functional, and phenotypic data in order to predict the biological activity of compounds.... continue reading >>


First molecules discovered by next-generation artificial intelligence to be developed into drugs


2017-07-27
First molecules discovered by next-generation artificial intelligence to be developed into drugs InSilico Medicine, Inc.

IMAGE: This is the overview of Pharma AI drug discovery pipeline. view more Credit: Insilico Medicine

Thursday, July 27, 2017, Baltimore, Md., Insilico Medicine ("Insilico"), a Baltimore-based leader in artificial intelligence ("AI") for drug discovery and biomarker development, is pleased to announce a multi-year drug development agreement with the biotechnology company... continue reading >>



Shooting the achilles heel of nervous system cancers


2017-07-20
20-Jul-2017 Shooting the Achilles heel of nervous system cancers Dartmouth-led research is in early-phase drug discovery and finds promising therapeutic leads after targeting vulnerabilities in nervous system tumors, including glioblastoma Dartmouth-Hitchcock Medical Center

IMAGE: Brain tumor cells after treatment with Y100, which causes depolarization of mitochondria and the appearance of mitochondrial 'hot spots' (red). view more Credit: Yolanda Sanchez

LEBANON, N.H. - Virtually all... continue reading >>




Copyright © 2017 Impact Journals
Impact Journals is a registered trademark of Impact Journals, LLC